Overview

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Status:
Terminated
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center